Cell & Gene Therapy Bioprocessing & Commercialization is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Miguel Forte
CEO at Zelluna Immunotherapy, Norway

Profile

CEO of Zelluna Immunotherapy, Chief Commercialization Officer, Chair of the Commercialization Committee and Member of Board of Directors of the International Society of Cellular Therapy (ISCT) and visiting Professor at the Lisbon University in Portugal. Member of the Board of Directors of the Alliance for Regenerative Medicine. Formerly CMO, Bone Therapeutics and COO and CMO of TxCell. From February 2006 to January 2010 was VP of Global Medical Affairs at UCB. In 2004, joined Nabi Pharmaceuticals as the VP of Clinical, Medical and Regulatory Affairs in Europe. After several clinical, academic and regulatory positions in the public sector in Portugal and at the EMA, spent six years with Bristol-Myers Squibb in various positions including Country Medical Director, Executive Director of Infectious Diseases, Immunology and Dermatology and VP of International Medical Organization in Portugal and Belgium. Holds an M.D. from the Faculty of Medicine of the University of Lisbon, Portugal, and a Ph.D. in Immunology from the University of Birmingham, UK, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies (HEP). He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.


Miguel Forte's Network

Agenda Sessions

  • Rapid clinical plans and anticipating process change

    ,
  • Chairperson's Opening Remarks

    ,
  • Chairperson's Opening Remarks

    ,
  • Chairperson's Opening Remarks

    ,